FibroGen (NASDAQ:FGEN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of FibroGen (NASDAQ:FGEN) to a hold rating in a report released on Saturday morning.

FGEN has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $250.00 price target on shares of FibroGen in a report on Tuesday, May 13th. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Tuesday, April 1st.

FibroGen Trading Down 6.1%

NASDAQ FGEN opened at $5.40 on Friday. The firm has a market cap of $21.82 million, a price-to-earnings ratio of -2.16 and a beta of 0.83. The company has a 50 day moving average of $7.52 and a 200-day moving average of $9.91. FibroGen has a 1-year low of $4.50 and a 1-year high of $38.25.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($4.00) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($4.75). The company had revenue of $2.70 million for the quarter, compared to analyst estimates of $2.00 million. On average, analysts forecast that FibroGen will post -0.8 earnings per share for the current year.

Institutional Trading of FibroGen

Institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new stake in FibroGen during the 4th quarter worth $205,000. Two Sigma Investments LP grew its holdings in FibroGen by 19.6% during the 4th quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 98,888 shares during the period. Two Sigma Advisers LP grew its holdings in FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares during the period. Mackenzie Financial Corp grew its holdings in FibroGen by 416.6% during the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 441,083 shares during the period. Finally, Two Sigma Securities LLC acquired a new stake in FibroGen during the 4th quarter worth $27,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.